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ABSTRACT
Dendritic Cells (DCs) are key regulators in autoimmunity. DCs function as antigen 
presenting cells (APCs) and are present in trace amounts in virtually all organs of the 
human body. DCs activate and regulate naive T cell function by inspecting T cell 
function to identify specific T cells for the antigen presented on the DC surface as 
peptide-MHC molecules.
Currently DCs harvested from blood and bone marrow possess individual variability 
in function and phenotype expression. Thus the need for standardised DC model is 
essential to enable more efficient and controllable studies into DC function as key 
immunoregulatory cells.
Previous studies have shown myeloid DCs generated from MUTZ-3 myeloid 
leukaemic cell line precursors to be a potentially suitable model for DC function 
studies.
In this study we aimed to establish MUTZ-3 as a model for DCs by incubating with 
various cytokines (TPO, IL-3, FLT3L, MCSF and SCF). The phenotype of the 
MUTZ-3 was analysed by flow cytometry to ensure the monocyte surface marker, 
CD14+, was optimally expressed. Further differentiation of these monocytes to 
immature DC was investigated by stimulating the MUTZ-3 with GM-CSF and IL-4.
The results obtained are preliminary and require repeating, however, most have been 
shown to be reproducible. It was observed that cytokines can differentiate MUTZ-3 to 
optimise CD14+ monocytic expression. In addition, GM-CSF and IL-4 were shown to 
differentiate these monocytes to immature-DC. Finally, retinoic acid was used to 
differentiate the MUTZ-3. However, it is vital to continue investigating to establish 
the most efficient method for CD14+ expression is optimised.
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1.1 The role o f Dendritic Cells (DCs)
DCs function as antigen presenting cells (APCs) and are present in trace amounts in 
virtually all organs o f the human body. DCs activate naive T cells in vivo and in vitro 
by inspecting T cell function to identify specific T cells for the antigen presented on 
the DC surface as peptide-MHC molecules (Howard et al., 2004). Some DCs are 
equipped with additional mechanisms to regulate the response of the T cells they 
activate, while others can interact with B cells and modify B cell responses (Dubois et 
al., 1999). DCs can also decommission T cells if  they present a threat to the integrity 
of the host, thus if the tolerogenicity o f DCs could be reliably exploited, they could be 
administered for autoimmunity, while enhancing their immunogencity could enable 
them to act against tumour-associated antigens (Liu et al., 2001; Morrison, III et al., 
2003; Mahnke and Enk, 2005).
1.1.1 Major function o f  DCs
DCs have been identified from various populations and defined due to their origin and 
general properties. All types of DCs appear to pass through several levels of 
maturation during their life-span. Immature DCs express low levels o f major 
histocompatibility complex (MHC) class II and co-stimulatory molecules; however, 
the surface expression of these glycoproteins is dramatically up-regulated during 
maturation in response to appropriate stimuli. Additionally, terminally differentiated 
DCs express specific maturation markers, such as MHC Class II and CD83 on human 
mature DCs (Frasca et al., 2003; Rescigno et al., 1998; Kawamura et al., 2005; 
Moghaddami et al., 2005).
2
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Peripheral DCs are specialised to endocytose or macropinocytose antigens and 
pathogens, whereas maturating DCs lose this ability but significantly enhance their 
stimulatory properties for naive CD4 T cells. Research has shown that liver-derived 
DCs and lymphoid-derived DCs are also able to down-regulate immune responses 
(Takahara et al., 2002; Dieckmann et al., 2005; Li et al., 2005). However, these 
contrasting subtypes of DCs are represented almost exactly by their immature 
phenotype (i.e. C D la+C D 14\C D 40\ CD54\ CD80\ CD86 and low Class II+).
Immature DCs exist in peripheral tissues, where they monitor foreign antigens and 
microbial pathogens. Once activated, immature DCs undergo maturation and migrate 
to the lymph nodes. DC maturation involves the redistribution of MHC molecules 
from intracellular endocytic compartments to the cell surface, a selective reduction of 
antigen acquisition and a significant increase in the surface expression o f clusters of 
differentiation (CD) molecules. During maturation DC morphology alters with the 
development and reorganisation o f the cytoskeleton to form dendrites, as well as the 
surface expression of various chemokine and integrin receptors. These enable the 
mature DCs to prime naive T cells and initiate primary T cell-mediated immune 
responses (Ross et al., 2000; Al Alwan et al., 2001). Thus, DCs play a crucial role 
during the initiation and regulation o f immune responses.
1.1.2 Sources o f DCs
Dendritic cells are most commonly harvested from bone-marrow or peripheral blood, 
for experimental and clinical studies. (Ashton-Chess and Blancho, 2005; Sato et al., 
1998). This method provides a reasonable number o f monocyte-derived DCs to be 
obtained. Such DCs remain stable and can be matured, which is preferable for the
3
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purpose of immunotherapy. Harvesting and deriving DCs by this method also reduces 
the possibility of infection or immunogenic reaction that might exist when proteins 
such as foetal calf serum (FCS) are added to maintain DCs in culture (Lehner et al., 
2005). This is because any addition to cells in culture requires careful aseptic 
technique and also proteins such as FCS can clump in suspension and this can lead to 
increased debris. Despite this method being the common one, DCs have still not been 
standardised. Research shows that DCs generated by monocyte derivation are 
dependent on certain cytokines as well as the culture media, though the role o f culture 
media in DC generation is unclear (Encabo et al., 2004; Masterson et al., 2002) .
There are at least two distinct sources of DC precursors present in human blood: the 
myeloid and lymphoid DC precursors (Sato et al., 1998). However, DCs have a great 
deal o f plasticity in their expression and influence of T cell responses, thus the 
concept of different DC lineage and function has been increasingly studied.
1.1.3 DC phenotype expression
Research has shown that the DC precursor cells are non-adherent and negative for 
MHC class II whilst mature DCs expressed high levels o f MHC class II, displayed 
dendritic morphology (e.g. dendrites) and were efficient stimulators o f allogeneic T 
lymphocytes (Reid, 1997; Moghaddami et al., 2005; Kawamura et al., 2005; Hubert et 
al., 2004; Frasca et al., 2003). Mature DC phenotype has been characterised by 
surface expression of CD14'CDla+ or CD14+C D llc ', high MHC class II, CD80+, 
CD83+ and CD86+.
4
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In DCs, unlike in other APCs, the MHC class II peptide complexes are transported to 
the cell surface during maturation, therefore immature DCs express lower MHC class 
II on their surface as most molecules remain in late-endosomal and lysosomal 
compartments whereas in mature DCs, almost all MHC class II molecules are 
expressed at the cell surface.
1.2 Cytokines
Cytokines include lymphokines produced by lymphocytes, monokines produced by 
monocytes and macrophages and interleukin produced when one cytokine from a 
leukocyte acts on other leukocytes. Cytokines are soluble extra-cellular hormone-like 
proteins that act as intracellular chemical mediators to regulate the intensity and 
duration o f immunity, inflammation, and haematopoiesis by acting locally in a 
paracrine or autocrine rather than endocrine manner, over short distances and short 
time spans at very low concentration. They bind to specific membrane receptors, 
causing the cell to alter gene expression via second messengers such as tyrosine 
kinases. Cytokines can vary in activity, however many are redundant in their activity, 
meaning similar functions can be stimulated by different cytokines, whilst others are 
produced in cascade when one cytokine stimulates the production of another. 
Cytokines are also able to act synergistically when two or more cytokines are required 
for a specific effect, or in contrast, antagonistically when the cytokines oppose each 
others activities (Zou and Tam, 2002; Masterson et al., 2002).
1.2.1 Cytokine receptors
Growth factors and cytokines are often linked due to their similar receptors, for 
example, growth hormone is considered by many to be a cytokine because the growth
5
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hormone receptor is similar to the cytokine receptors. The subfamilies of cytokines 
are formed either by their function or histology. For example interleukins (IL) IL-3, 
IL-5 and granulocyte macrophage colony stimulating factor (GM-CSF) are classed in 
a family due to their unique cytokine-specific receptor.
Haematopoietic cytokine receptors have been characterised as having two subunits, 
one cytokine-specific and one signal transducing. Thus, for example, these two 
subunits can dimerise when either GM-CSF or IL-3 bind with low affinity while 
another subunit signal transducer increases cytokine-binding affinity. This dimerised 
unit associates with tyrosine kinases in the cytoplasm which through phosphorylation 
activates transcription of effector proteins. GM-CSF and IL-3 act on haematopoietic 
stem and progenitor cells to induce monocyte activation and immature DC 
differentiation. GM-CSF has been shown to be the key cytokine for the final 
maturation process of DCs, while macrophage colony-stimulating factor (MCSF) has 
been shown to be ineffective (Zou and Tam, 2002).
MSCF, Stem cell factor (SCF) and FLT3-ligand (FLT3L) are early acting cytokines 
which share similar receptors that have tyrosine kinase activity and are expressed on 
primitive progenitor cells. Research using suspension cultures and assays o f human 
CD34+ haematopoietic cells suggests that addition of either SCF or FLT3L leads to 
higher DC production than with only GM-CSF and IL-4 (Encabo et al., 2004). 
However, it is still unclear whether FLT3L, MCSF and SCF are act as solely 
synergistic factors that enhance DC production by expanding already committed 
lineage-restricted precursors, or whether they act as permissive factors by inducing 
proliferation o f very primitive haematopoietic cells that then become capable of
6
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responding to GM-CSF and IL-4. GM-CSF and IL-4 function to differentiate mature 
and functional myeloid DC from early human progenitors (Kelly-Welch et al., 2005). 
This function is said to be diminished in the absence of early acting cytokines. 
Research on bone marrow cell lines has shown early acting cytokines such as MSCF, 
SCF and FLT3L cooperate with GM-CSF to induce and maintain long-term DC 
differentiation (Sumimoto et al., 2002; Hope et al., 2000). FLT3L has been shown to 
substantially increase the number of myeloid DCs in the blood of mice and that it also 
increases the numbers of myeloid DCs. FLT3L is known to act synergistically with 
thrombopoietin (TPO) to induce in vitro generation of large numbers of CD14+ 
monocytes and CD1 lc+ immature DCs (Hope et al., 2000).
1.2.2 The effect o f  cytokines on DC lineage
Immature DC are found in peripheral tissues and are characterised by high ability to 
acquire antigens, high intracellular MHC class II expression, and low expression of 
co-stimulatory molecules such as CD86. When DC maturation occurs, the acquisition 
of antigens is down-regulated, while the surface expression o f co-stimulatory 
molecules is up-regulated and MHC class II molecules are translocated from 
intracellular compartments to the cell surface. As DCs are rare in vivo, most of the DC 
maturation studies have been conducted in vitro (Weigel et al., 2002; McRae et al., 
2000). DCs can be harvested in vivo from blood or bone-marrow, however, the in 
vitro administration of the hemopoietic growth factors (such as FLT3L, IL-3 and GM- 
CSF) permits a greater number of DCs to be generated in vitro. Increasingly research 
on DCs is being conducted on larger populations of DCs from either CD34+ 
proliferating progenitors or CD14+ non-proliferating monocytic precursors (Zou and 
Tam, 2002; Ratta et al., 1998).
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Human CD34+ haematopoietic progenitor cells that have been purified from blood or 
bone-marrow have been shown to differentiate into DCs after stimulation with 
cytokines GM-CSF and IL-4. However, both SCF and FLT3L have been able to 
increase the DC yield as they probably expand the precursor cells, rather than 
inducing DC differentiation.
Studies on progenitor cells show that monocytes are able to develop into macrophages 
or develop directly into DCs. Blood monocytes can be induced to differentiate into a 
form of DCs. The treatment o f these monocytes with GM-CSF and IL-4 produces 
monocyte-derived DC with an immature DC phenotype, and these immature DCs can 
undergo maturation when stimulated by other signalling molecules such as 
lipopolyssacharide (LPS) (Espuelas et al., 2005).
Figure 1. Myeloid-related DC development pathways. This illustration, courtesy of Berlex, 
depicts the diverse pathways for DC formation. The two myeloid-derived pathways: one 
directly from blood monocytes without division and the other by division and differentiation 
of a common myeloid precursor cell, all under the influence of GM-CSF.
9
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As seen in figure 1, myeloid DCs of are close relatives of macrophages and may be 
generated by different developmental pathways. Much research is continuously being 
conducted to establish whether these differences in origin influence the biological 
function of DCs. The DCs generated by each lineage have been shown to display 
functional specialisations as well as presenting antigens to activate naive T cells. 
These differences make it harder to standardise DC functions.
1.2.4 Clinical importance o f  DCs
DCs are the only APC that can initiate immune response. Therefore, science aims to 
exploit this attribute to enable DCs to be used for antigen-specific immunotherapies 
for cancers and infectious diseases (Grunig et al., 2005; Hayashi et al., 2005). Thus 
monocyte-derived immature DCs isolated from a patient are loaded with antigen using 
synthetic peptides, dead tumour cells or infected cells after which they are matured 
and injected into patients during clinical trails (Figure 2).
Generation of immature Isolation of monocytes 
dendritic cells from peripheral blood
Loading of 
dendritic celts 
with whole cell 
tumor-lysate Lysate
preparation
Patient
Vaccination of the patient
Mature, antigen-presenting 
dendritic cells
Figure 2. Shows the use o f DCs in clinical applications. (H.Bohnenkamp, 2004)
Vaccination with DCs leads to protective immunity against infections and tumours.
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1.2.5 The importance o f a dendritic cell model
A DC-like model cell line would provide a standard on which to base investigations. 
This is because DCs are of heterogeneous hemopoietic lineage, in that subsets from 
different tissues have been shown to possess considerable variability in morphology, 
phenotype and function. Therefore, recent studies are aimed at developing DC-like 
cell line models to establish reproducible and efficient methods to generate adequate 
numbers of fully functional DCs for clinical applications (Berges et al., 2005).
1.3 MUTZ-3 as a potential DC-like model
New in vitro research by Masterson et al. shows that myeloid DCs, generated from 
leukaemic cell line precursors expressing CD34+, can develop into Langerhan or 
interstitial DCs. Masterson et al. have suggested that this may also share a potential 
for differentiation to DC-like APCs, thus providing a ready supply o f DC precursors 
from which DCs can be efficiently generated. This cell line has been derived from 
tumours of myeloid lineage and named MUTZ-3: a continuous human leukaemia cell 
line with a round blast-like non-adherent morphology that grows as single cells 
(Masterson et al., 2002).
MUTZ-3 (Deutsche Sammlung von Mikroorganismen und Zellkulturen [DSMZ], 
Braunschweig, Germany) is a cell line containing mixed population of myeloid cells 
at varying stages of differentiation. The DSMZ cell catalogue states that MUTZ-3 
phenotype is known to be CD3", CD4", CD5", CD7", CD8", CD 10", CD lib", CD13+, 
weak CD14+, CD15+, CD16", CD19", CD20", CD25", weak CD30+, CD33", CD34+, 
CD38+, CD41a, CD42b", CD56", CDw65+, CD68+, CD71" and low MHC-Class II+. 
MUTZ-3 also express monocyte-specific esterase (MSE), myeloperoxidase (MPO)
11
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and tartrate resistant acid phosphatase (TRAP) enzymes, thus exhibiting monocytic 
behaviour (Hu et al., 1996). Hu et al. have also shown that MUTZ-3 can undergo 
sustained and continuous growth with the addition of cytokines to the culture medium 
and must be grown in conditioned medium for proliferation and survival. GM-CSF, 
M-CSF, SCF and IL-3 have been shown to be the most effective growth factors in 
inducing proliferation and differentiation o f MUTZ-3. Also, Hu et al. exposed 
MUTZ-3 to phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate (TPA) and the 
physiological all-trans retinoic acid (ATRA), and both had growth-inhibitory and 
differentiation-inducing effects on MUTZ-3 (Hu et al., 1996).
As mentioned above, MUTZ-3 cell line can only undergo sustained and healthy 
growth when conditioned medium is present. This conditioned medium is sourced 
from a secondary cell line: The 5637 cell line is an epithelial-like adherent cell line 
which has been described as producing various growth factors (e.g. SCF, IL-1, IL-6, 
GM-CSF, etc) and though the exact cocktail of factors is unknown, the medium from 
5637s is crucial for the development and growth of the MUTZ-3 cell line (Masterson 
et al., 2002).
MUTZ-3 has been reported to down-regulate CD 14 expression when stimulated by 
IL-4 and GM-CSF and thus is valuable for investigating the complex cytokine and 
molecular signalling pathways of DCs (Hu et al., 1996; Quentmeier et al., 1996). This 
cell line has also been shown to acquire a phenotype consistent with either interstitial 
or Langerhan-like DCs (CD83+) when stimulated by specific cytokine cocktails. 
Masterson et al. have suggested that MUTZ-3-derived DCs display the functional 
MHC complexes and antigen markers, therefore, MUTZ-3 cells could provide an
12
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unlimited source o f CD34+ DC progenitors which could be used for research into 
cytokine-induced DC differentiation and DC functional studies (Hu et al., 1996; 
Steube et al., 2000; Quentmeier et al., 1996; Kharfan-Dabaja et al., 2005; Fazekas De 
St et al., 2002).
13
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1.4 Aims
Most studies on DC function and molecular pathways have been conducted on DCs 
harvested from human or mouse blood and bone-marrow. These possess too much 
individual variability and the process to purify DCs from blood is inefficient with only 
a limited number o f cells being available for research despite taking a relatively long 
time to process the blood or bone-marrow. Thus the need for a standardised DC model 
is essential to enable more efficient and controllable studies into DC function as key 
immunoregulatory cells.
Previous studies have suggested MUTZ-3 to be a potentially suitable model for DC 
function studies(Reid, 1997). Therefore it is important to independently establish a 
model to generate a supply o f dendritic-like cells based on today’s understanding of 
DCs and their progenitor lineages.
As DCs cannot proliferate or differentiate further, it is important to maintain a model 
cell line which could viably be grown in mass and induced to differentiate into DCs 
when required for DC studies. Therefore, we aim to bulk MUTZ-3 cell stocks and 
induce differentiation o f MUTZ-3 precursors to monocytes. As CD 14 is a key marker 
expressed on the surface of monocytes, we aim to optimise the yield of CD14+ 
monocytes from MUTZ-3 cultures using various cytokine cocktails. Also, we aim to 
demonstrate that MUTZ-3 monocytes can be differentiated to immature DC using 
GM-CSF and IL-4.
This initial data will help us optimise a model for the study of dendritic cell signalling 
pathways & thus molecular events initiating adaptive immunity.
14
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2.1 Solutions and Materials
Complete aMEMH
Complete aMEM'
Complete RPMI
Formaldehyde
Complete HBSS
Retinoic Acid
SIGMA® aMEM containing 20% (v/v) FBS,
10pg/ml penicillin/streptomycin and 10% (v/v) 
conditioned medium of cell line 56371
SIGMA® aMEM containing 20% (v/v) FBS and 
1Opg/ml penicillin/streptomycin
GIBCO™ RPMI 1640 containing 10% (v/v) FBS 
and 10pg/ml penicillin/streptomycin + 2mM L- 
Glutamine
3.7% (v/v) formaldehyde in HBSS. (Sourced from 
Jane Rasaiyaah)
Containing 10% filtered human serum and 0.1% 
sodium azide
lpM , lOOnM, lOnM in complete aM EM +/- 
conditioned medium of cell line 5637. (Sourced 
from Jane Rasaiyaah)
Cytokines: Bought as 2pg each from www.immunotools.com
TPO, IL-3, FLT3L, MCSF, Each diluted in aMEM to give 25ng/ml.
SCF : 40pl stored in 1ml cryogenic vials at -80°C.
1 5637 is an epithelial-like adherent cell line from human urinary bladder carcinoma 
established from the primary bladder carcinoma of a 68-year-old man in 1974. Cells described 
to produce several growth factors (e.g. SCF, IL-1, IL-6, G-CSF, GM-CSF, etc.)
16
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Conjugated antibodies and their specificity for flow cytometry
CD la PE-conjugated anti-human IgG
CD3 APC-conjugated anti-human IgG
CD13 PE-conjugated anti-human IgG
C D llc APC-conjugated anti-human IgG
CD14 APC-conjugated anti-human IgG
PE-conjugated anti-human IgG
CD19 PE-conjugated anti-human IgG
CD45 APC-conjugated anti-human IgG
Class II PE-conjugated anti-human IgG
Secondary Antibody PE-conjugated anti-human IgG
N.B:
All conjugated antibodies were purchased from BD Pharmigen™ in 2ml vial. These 
were diluted as required at the time of use -  this was dependant on their effectiveness 
which was tested by a titration of antibody concentration (data not shown) - majority 
of the antibodies were diluted 10pl-15pl in 50pl of HBSS at the time of use.
The non-conjugated monoclonal antibodies (CDla, CD3, C D llc , CD14, CD45, 
CD83, CD86, Class I and Class II) were sourced from Jane Rasaiyaah.
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2.2 Preparation o f 563 7 conditioned media
5637 adherent cell line was maintained alongside the MUTZ-3 and its medium stored 
in 5ml aliquots at -80°C for use in complete aMEM+.
The 5637s were cultured in complete RPMI for 7 days at 37°C till 95% confluency. 
The culture medium was aspirated from the 150mm dish into a 50ml Falcon tube. 
Then 4ml trypsin was added to the dish and incubated for 5-7 minutes till the cells 
where visibly in suspension. This trypsinised suspension was quenched in 3ml 
complete RPMI in a 15ml Falcon tube. The cells where harvested by centrifugation of 
the cell suspension for 10 minutes at 1200rpm to remove debris. The previously 
aspirated medium was also centrifuged and the supernatant transferred to a fresh 50ml 
Falcon tube and centrifuged again to remove all cell and debris content. The cell pellet 
from the quenched suspension in the 15ml Falcon tube was then resuspended to split 
the cells 1:2 dilution in complete RPMI and returned to the incubator (37°C, 5% CO2) 
to culture for 7 days. Finally the conditioned medium from the 50ml falcon tube was 
transferred to 5ml Bjoux tubes and stored at -80°C till required.
2.3 MUTZ-3 culture
At 95% confluency, MUTZ-3 non-adherent cell culture was aspirated from T25 flask 
into a 15ml Falcon tube and centrifuged for 10 minutes at 1200rpm. The supernatant 
was discarded and the cell pellet resuspended for a 1:2 split by resuspending cells in 
4ml complete aMEM+. Finally 2ml/flask was transferred to 2 fresh T25 flasks 
containing 8ml media complete aMEM+. These flasks where incubated horizontally 
for 4-5 days at 37°C and 5% CO2 saturation with a density of 1.5x106 cells/flask.
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2.4 Cell Counting
Viable cells were counted using a Neubauer Improved Haemocytometer by trypan 
blue (0.4%, Sigma®) exclusion and phase contrast microscopy.
2.5 Staining MUTZ-3 for phenotypic expression
The MUTZ-3 cells were bulked up to 95% confluency in a T25 flask before being 
analysed by flow cytometry.
MUTZ-3 cells were transferred into a 15ml Falcon tube, counted and 6x l05 cells were 
centrifuged at 1200rpm for 10 minutes. The supernatant was disposed o f and the cell 
pellet resuspended in 600pl o f complete HBSS (lOOp 1/stain). After incubating for 50- 
60 minutes on ice, the cells were transferred to 10 wells o f a 96-well round-bottomed 
plate (lOOjul/well). Leaving one well unstained, the remaining 9 wells were 
individually incubated for 60 minutes with primary non-conjugated monoclonal 
antibodies. Then the cells were washed by pipetting 50pl complete HBSS into each of 
the 10 wells and the plate centrifuged at 1800rpm for 5 minutes before flicking the 
supernatant off carefully so as to not lose cell pellets - this was repeated 3 times. Then 
(PE labelled) secondary antibody was pipetted into each of the 5 wells and this was 
incubated on ice for 60 minutes (figure 3) before being fixed and analysed by flow 
cytometry (see section 2.9). This experiment was repeated three times to ensure the 
viability of data.
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Fluorescence 
Labelling 
(PE) r
Monocytes CD 14 Primary Secondary
CD 14+ antibody antibody
Figure 3. Flow cytometry using non-conjugated antibodies. Monocytes expressing, 
fo r  example CD14+, are incubated with primary monoclonal antibodies for an hour 
followed by lh r incubation with secondary antibodies that are conjugated to 
florescence markers.
2.6 Preparation o f  MUTZ-3 fo r  10 day stimulation by cytokines with 
conditioned medium
MUTZ-3 cells were aspirated from the T25 flask into a 15ml Falcon tube and counted. 
Then 6xl05 cells were centrifuged for 10 minutes at 1200rpm and resuspended in 6ml 
complete aMEM+. lxlO5 cells/well were seeded into 6 wells of a 12 well plate. Next 
lOpl (25ng/ml) of the relevant cytokines (see figure 4) were added to each well as 
follows:
- To the first well all 5 cytokines (TPO, IL-3, FLT-3L, MCSF and SCF) were 
added.
- To subsequent 5 wells, only 4 cytokines were added - leaving out 1 different 
cytokine in each well.
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The 12 well plate was incubated for 2 days at 37°C with 5% CO2 after which 1ml 
complete aMEM+ was added to each well and lOpl of cytokines were added to each 
well (in the same order as before). After further 2 day incubation the cells were 
transferred respectively from the 12 well plate wells into those of a 6 well plate, 1ml 
complete aMEM+ was added to each well and lOpl o f cytokines were added to each 
well (in the same order as before). After 3 days incubation the cells were transferred 
from their wells into 6 separately labelled 50mm dishes. Each dish had 1ml complete 
aMEM+ added and lOpl of cytokines added to each dish in the correct order. These 
plates were incubated for 2 days before being FACS stained (see figure 4).
2.6.1 Preparation o f MUTZ-3 for 10 day stimulation by cytokines w/o conditioned 
medium
The MUTZ-3 cells were prepared as explained above, but complete aMEM+ was 
replaced at every stage by complete aMEM'.
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-FLT3L
+ TPO, IL3, MCSF & SCF
All
Cytokine
-MSCF
+TPO, IL3, SC F &
-TPO
+IL3, MCSF, SC F & FLT3L
-SCF
+TPO, IL3, MSCF & FLT3L
-IL3
+TPO, MCSF, SC F &
2 days: Add 1 ml m edia & 10fd cytokines
All Cytokines
-IL3
+TPO, MCSF, SCF & FLT3L
-TPO
+IL3, MCSF, SCF & FLT3L
-FLT3L
+ TPO, IL3, MCSF & SCF
2 days: Add 1ml media & 10 i^l cytokines
-MSCF
+TPO, IL3, SCF & FLT3L
-SCF
+TPO, IL3, MSCF & FLT3L
3 days: Add 1ml media & 10^1 cytokines
50mm Plate
X 6
Figure 4. Diagram to show the various stages and setup of MUTZ-3 
stimulated by cytokines for 10 days.
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2.7 Inducing differentiation o f MUTZ-3 monocytes to immature DC
MUTZ-3 cell line was stimulated with the addition of the 5 cytokine cocktail by 
pipetting lOpl of 25ng/ml concentration o f each cytokine into a culture of lx l0 5cells. 
This was repeated every 2 or 3 days for a total of 10 days, during which the cells were 
moved from a 12 well plate well to a 6 well plate to a 50mm dish (as explained 
previously). Then GM-CSF (lOOng/ml) and IL-4 (lOng/ml) were pipetted and 
incubated for 7 days at 37°C and 5% CO2 . These plates were then counted and the 
cells analysed by non-conjugated antibody single staining and flow cytometry.
2.8 Preparation o f MUTZ-3 for 12 hour and 24 hour stimulation by retinoic 
acid with conditioned medium
MUTZ-3 cells were aspirated from the T25 flask into a 15ml Falcon tube. The cells 
were counted, centrifuged for 10 minutes at 1200rpm and resuspended in complete 
aMEM+ so as to have 4x l05 cells/ml to ensure sufficient cells for 3 stains (each stain 
requiring lxlO 5 cells). Then 1ml was seeded into six 100mm plates. These plates were 
labelled as follows:
[Retinoic Acid] 12 hr incubation 24 hr incubation
lpM 4 x l0 5 cells total 4x l05 cells total
lOOnM 4xl05 cells total 4x l05 cells total
lOnM 4x 105 cells total 4x l05 cells total
2.8 1 Series dilution o f RA
The plates then had 9ml of RA titre added to them as shown in the table above. The 
varying concentrations o f RA were prepared by taking lOOpl from the lOOpM RA 
stock and adding to 9.9ml of complete aM EM 'to give a new concentration of lpM .
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Next a 1ml aliquot of lpM  RA was added to 9ml complete aMEM' giving a new 
concentration of lOOnM. Finally, a 1ml aliquot of lOOnM RA was added to 9ml of 
complete aMEM’ giving a concentration of lOnM (figure 5).
ljllM 1:100 l r n l  1:10 l r n l  1:10
100pM 
Stock RA
9.9ml
complete
MEM
9ml
complete
MEM
9ml
complete
MEM
l|iM  RA lOOnM RA lOnM RA
Figure 5. Dilution series o f  retinoic acid. The stock RA was diluted and each tube 
pipetted into a 100mm culture dish into which lrnl o f 4x10s cells was added.
The dishes were incubated for 12hrs and 24hrs: at each time point the cell suspensions 
from the three RA concentrations were individually counted before being centrifuged 
at 1200rpm for 10 minutes.
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Each cell pellet was then resuspended in 300pl complete HBSS blocking antibody for 
lhr after which lOOpl was aliquoted into a labelled 96-well plate to which conjugated 
antibodies were added and incubated for lhr. Then the cells were fixed and analysed 
by flow cytometry (section 2.9).
2.8.2 Preparation o f MUTZ-3 for 12 hour and 24 hour stimulation by retinoic 
acid n’/o conditioned medium
The MUTZ-3 cells were prepared as explained above, but using the complete aMEM' 
instead of complete aMEM+. The above procedure was repeated twice so a total of 12 
dishes were incubated (3 for 12hrs and 3 for 24hrs) before being FACS stained.
2.9 Flow cytometry analysis o f MUTZ-3
The stimulated MUTZ-3 cell suspensions from the six 50mm plates were aspirated 
into 6 separately labelled Falcon tubes and the cells o f each stimulation counted. The 
cells were diluted to lxlO 5 cells/stain and centrifuged at 1200rpm for 10 minutes. The 
cell pellets were individually resuspended in complete HBSS blocking antibody 
(lOOpl per stain). These were incubated on ice for 60 minutes before lOOpl/well was 
transferred into a 96 well round-bottom plate. Then a saturating amount (50pl) of 
conjugated antibodies diluted in complete HBSS was pipetted individually to each 
well (see section 2.1). This was conducted with the lights off to ensure minimal 
degradation of the conjugated antibody fluorescence, and the plate was then wrapped 
in foil before being incubating on ice for 50-60 minutes after which 50pl complete 
HBSS was added to each well and the plate centrifuged at 1800rpm for 5 minutes. 
The supernatant was then flicked out of the plate, being careful not to flick out cell 
pellets and also avoid drops re-entering wells. A second wash by adding 50pl 
complete HBSS and centrifuging at 1800rpm for 5 minutes followed by flicking off
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supernatant ensured any contamination through unbound or unspecific binding did not 
occur. Finally, to fix the cells, 50pl complete HBSS and lOOpil of 3.7% (v/v) 
formaldehyde in complete HBSS was individually pipetted into each well and the 
cells transferred to a labelled flat-bottomed 96 well plate. The plate was then wrapped 
in foil, stored in the fridge and run on the FACS machine within 5 days. (N.B: the 
cells were carefully resuspended each time when adding solution to wash or fix).
The flow cytometry was performed for 10,000 events per sample on a BD Biosciences 
BD FACS Array'M bio-analyser using a green (532nm) and red (635nm) laser (PE 
575nm, APC 600nm) and analysed using WinMDI software.
This bio-analyser is able to compensate for any cross-channel spill-over, and was 
setup so that the unstained and single colour positive controls for each channel 
(CD45APC and CD13PE) were adjacent to each other. These were followed by the 
negative isotype stains for each channel (CD3APC, CD19PE).
1 2 3 4 5 6 7 8 9 10 11 12
b Q O O O Q O Q O O O O A-----
c 0 0 0 0 0 0 0 0 0 0 0 ^ , 3  con„,
D Q  Q  Q  Q  Q  0  0  0  0  O  P  -  D3 APC ^  ^  
E C 3  C - )  O O O C 3  O O O C -ve C D 1 9 |j Isotype control
F O O O O O O O O O O C  Samples
° O O O O O O O O O O C ^  . C D 14P E /C D llc  APC
hO O O O O O O O O O C  CDlaPE/CDI4APC
Figure 6. 96-well layout fo r  FACS. Diagram shows the contents and order o f the 
wells to enable the FACS machine to compensate fo r  spill-over and ensure correct 
flow  cytometry analysis.
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CHAPTER 3
Preparation of MUTZ-3 for phenotype staining
3.1 Introduction
3.2 Results and Discussion
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3.0 Preparation o f MUTZ-3 for phenotype staining
3.1 Introduction
MUTZ-3 has been shown to exhibit dentritic-like properties when induced by growth 
factors. It is crucial however, to understand the phenotype of MUTZ-3 pre-stimulated 
by additional growth factors. It was crucial to understand the phenotype o f the initial 
population of MUTZ-3 against which further stimulated MUTZ-3 phenotypes could 
be compared.
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3.2 Results and Discussion
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Figure 7. Phenotypic stain o f MUTZ-3 cells. Flow cytometry analysis o f the initial 
population o f MUTZ-3 grown to 95% confluency in a T25 flask. This was repeated three 
times.
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Data set Surface Marker Expression
CD3 CD14 C D llc CDla Class I Class II
1 0% 18% 10% 0% 100% 54%
2 0% 23% 10% 0% 91% 55%
3 2% 19% 11% 0% 100% 52%
MEAN 1 ± 0.7% 20 ± 1.5% 10 ±0.3% 0 ± 0% 97 ± 3% 54 ± 0.9%
Table 1. Summary o f the repeated flow cytometry data representing the phenotype 
of unstimulated MUTZ-3. The mean percentages with the standard error o f  mean 
have been calculated.
CD3 is a marker for all T lymphocytes, which includes T helper cells, T suppressor 
and cytotoxic cells. The MUTZ-3 monocytes do not express CD3, thus CD3 was used 
as a negative isotype (0%) for the MUTZ-3 population. This enabled the correct setup
of the FACS machine, by adjusting the voltages causing the CD3 peak to shift into the
1 2initial 10-10 log phase of the PE (yellow) channel output. Subsequent markers were 
then compared against the CD3 and unstained cells. In the final repeat the FACS 
machine voltage could not be adjusted sufficiently. Therefore giving rise to 2% CD3+, 
however, this is most likely due to debris or dead cells causing auto-fluorescence, 
hence the standard of error of mean of ± 0.7%.
CD 14 antigen is found on myelomonocytic cells and is strongly expressed on 
monocytes. The CD 14 marker is useful for the detection of adherent myonocytes in 
normal peripheral blood and in disease states such as the identification of leukaemia 
and lymphoma cells of monocytic and myelomonocytic origin. It is present on blast
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cells from patients with myelomonocytic leukaemia. CD 14 is weakly expressed on B- 
lymphocytes and neutrophils, but not expressed on T-lymphocytes, red blood cells 
and platelets. Thus, we would expect to have expression of CD 14 on the monocytes 
present in the MUTZ-3 population; hence CD14+ is seen to be weakly expressed at 
only 20 ± 1.5%.
CD1 lc is a specific marker for monocytes and DCs, thus it is weakly expressed (10 ± 
0.3%) in the mixed population of MUTZ-3. This suggests some cells in the MUTZ-3 
population are exhibiting monocytic expression. Thus CD14+C D llc + monocytes are 
present in the initial pre-stimulated MUTZ-3 culture.
CD la is a human epidermal immature DC marker related to class I MHC molecules 
and responsible for presenting glycolipid and lipid antigens to T cells. However, the 
mixed population o f MUTZ-3 are all CD la' (0%), hence there are no immature DC 
present.
All haematopoietic cells express Class I surface antigen. All the initial pre-stimulated 
MUTZ-3 population expressed Class I (97 ± 3%) because MUTZ-3 is a 
haematopoietic cell line. MHC class II, however, is only expressed by a smaller 
subset of haematopoietic cells, hence 54 ± 0.9% Class II+ cells. This is due to most the 
Class II remaining intracellular till the cells differentiate and mature further to mature 
DCs.
We can conclude that the phenotype of unstimulated MUTZ-3 precursors is low Class 
II+, Class I++, weak CD14+ and even weaker CD1 lc+.
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CHAPTER 4
Inducing differentiation o f  MUTZ-3 by stimulating with 
cytokines
4.1 Introduction
4.2 Results and Discussion
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4.0 Inducing differentiation o f MUTZ-3 by stimulating with cytokines
4.1 Introduction
MUTZ-3 can be induced to behave DC-like when stimulated with growth factors such 
as cytokines. Indeed, the MUTZ-3 cell line must be cultured in conditioned media of 
cell line 5637 which are described as releasing various undefined cytokine growth 
factors such as SCF, IL-1, IL-6, GM-CSF, etc. It was important to establish the 
phenotype of MUTZ-3 after stimulation with specific cytokine cocktails. Therefore, 
the MUTZ-3 cell line was stimulated with the addition of 5 cytokines: TPO, IL-3, 
MSCF, SCF and FLT3L (see chapter 2 for further details).
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4.2 Results and Discussion
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Figure 8. Phenotypic stain o f MUTZ-3 cells before and after stimulation with cytokines.
Flow cytometry analysis of MUTZ-3 for the expression of CD3 (negative isotype control), 
CDla, CD llc and CD 14.
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Figure 9. Phenotypic stain o f MUTZ-3 cells before and after stimulation with cytokines.
Flow cytometry analysis o f MUTZ-3 for the expression o f Class /, Class II, CD45, CD83 and 
CD86.
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The 10 day stimulation of MUTZ-3 with cytokines was repeated three times. This 
data has been summarised in table 2.
Data set Surface Marker Expression
CD3 CD14 C D llc CDla Class I Class II
1 0% 35% 28% 3% 95% 52%
2 0% 40% 25% 1% 93% 54%
3 0% 40% 27% 1% 94% 54%
MEAN 0 ± 0% 38 ± 1.7% 27 ± 0.9% 1.7 ±0.7% 94 ± 0.6% 53 ± 0.7%
Table 2. Summary o f the repeated flow cytometry data representing the phenotype 
o f stimulated MUTZ-3. The mean percentages with the standard error o f  mean have 
been calculated.
Both unstimulated and stimulated MUTZ-3 populations were compared to each other 
to establish differences in phenotype after 10 day stimulation with the cytokine 
cocktail. The results show the MUTZ-3 had differentiated, leading to an increase of 
CD 14+ monocytes by approximately 20%, from 20 ± 1.5% unstimulated to 38 ± 1.7% 
stimulated. Thus, some MUTZ-3 precursors had differentiated with the addition of 
cytokines, thereby increasing the monocyte population.
C D l l c  expression also increased after 10 day stimulation with the 5 cytokines from 
10 ± 0.3% to 27 ± 0.9% after stimulation. As CDl l c  is a specific marker for 
monocytes and DCs, this 17% increase can be attributed to increased differentiation of 
MUTZ-3 precursors to monocytes induced by addition o f the cytokines.
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CDla  is a marker for immature DC. CDla  expression did not increase significantly 
(<2%), suggesting no differentiation o f monocytes to immature DC.
Class I expression was decreased by -3%  from 97 ± 3% to 94 ± 0.6% after 
stimulation., though Class 11 expression did not change significantly with a <1% 
decrease from 54 ± 0.9% pre-stimulation to 53 ± 0.7% post-stimulation, thus there 
were no mature DC present.
CD45 is a leukocyte common antigen which is expressed by the various subtypes of T 
cells and B cells as well as monocytes and macrophages. CD45 is present as two 
isoforms depending on exon banding, and these are denoted CD45RA and CD45RO. 
For this investigation only CD45RA was available to stain with, and after stimulation 
with cytokines CD45RA+ is 29%, which can be attributed to the monocyte population. 
However, as only CD45RA was used, 29% only represents half the CD45+ 
expression. Hence, it is important to repeat this stain with CD45RO and CD45RA or 
CD45, which contains both isoforms.
CD83 is a maturation marker for DC which is not expressed (-0% ) in the mixed 
population of MUTZ-3 after stimulation with all 5 cytokines. Therefore, suggesting 
that the 10 day cytokine stimulation only induces the cells to differentiate to 
monocytes and not induce maturation to mature DC. CD86 is a monocyte and DC 
marker which is expressed (-70% ) which can be attributed to the monocytes induced 
by the cytokine stimulation.
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CHAPTER 5
Stimulation of MUTZ-3 differentiation bv GM-CSF & IL-4
5.1 Introduction
5.2 Results and Discussion
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5.0 Stimulation o f  MUTZ-3 differentiation by GM-CSF & IL-4
5.1 Introduction
MUTZ-3 is a myeloid cell line, therefore, to establish whether the mixed population 
of MUTZ-3 can be differentiated to the immature DC-like phenotypic expression, the 
MUTZ-3 were stimulated for 10 days by the 5 cytokines (TPO, IL-3, SCF, M-CSF, 
FLT3L) and then a further 7 day stimulation with GM-CSF (lOOng/ml) and IL-4 
(lOng/ml) which are known to induce differentiation to immature DC (figure 10).
+/-TPO
+/-IL3
+/-MCSF
+/-SCF
+/-FLT3L
MUTZ-3 mixed population 
W eak CD14+
Monocyte
CD14++
+GMCSF & IL4
fmmature DC 
CD14'
Figure 10. Differentiation o f MUTZ-3. Diagram showing differentiation of MUTZ-3 induced 
by GM-CSF and IL-4.
39
M. I Haq MRes Biomedicine Summer 2005
5.2 Results and Discussion
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Figure 11. MUTZ-3 7 day stimulation o f MUTZ-3 with GM-CSF and IL-4 after 10 day 
stimulation with TPO, IL-3, SCF, MCSF and FLT3L.
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Figure 12. MUTZ-3 7 day stimulation o f MUTZ-3 with GM-CSF and IL-4 after 10 
day stimulation with TPO, 1L-3, SCF, MCSF and FLT3L.
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The GM-CSF and IL-4 induce the MUTZ-3 monocytes to differentiate into immature 
DC-like cells (Kelly-Welch et al., 2005; Reid, 1997). Immature DC are characterised 
by C D 14'C D llc+, low Class II and CD83' phenotype. In our investigation, this 
phenotype is observed by the down-regulation in expression of monocyte marker 
CD 14 by 20% from 36% to 16% after stimulation with GM-CSF and IL-4. Also, 
CD1 lc expression increases 7% from 21% to 28%. However, CD1 lc+ 21% relates to 
MUTZ-3 after 10 day stimulation with the cytokine cocktail, and when compared to 
data from table 2, which shows the mean CD1 lc expression is 27 ± 0.9% after 10 day 
cytokine stimulation, it is unclear whether the 7% increase in C Dl l c + in this 
experiment is due to experimental errors or significant due to differentiation to 
immature DC by the addition of GM-CSF and IL-4.
Also C D la+, a marker for DC-like cells, is up-regulated by almost 20%, suggesting 
that GM-CSF and IL-4 have induced differentiation of MUTZ-3 monocytes to 
immature DC-like cells similar to dendritic cells o f LC phenotype which have been 
shown as CD14'CDla+ (Mitsui et al., 2004). The 16% increase in Class II from 56% 
to 72% can also be attributed to the increased population of immature DC-like cells. 
CD45 expression remains unchanged (44%), however, the maturation marker, CD83, 
is not expressed significantly (<3%), therefore GM-CSF and IL-4 have not caused 
maturation of immature DC to mature DC.
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CHAPTER 6
Stimulating MUTZ-3 by varying cytokines
6.1 Introduction
6.2 Results and Discussion 
6.2.1 Spill-over compensation
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6.0 Stimulating MUTZ-3 by varying cytokines
Summer 2005
6.1 Introduction
Up till now the MUTZ-3 were stimulated with all 5 cytokines, however, this is a very 
expensive procedure as cytokines cost a great deal for a very small amount -  each vial 
of 2ml cytokines, once diluted to 25ng/ml, was sufficient for only two 10 day 
stimulations. It was important to establish which of the 5 cytokines was definitely 
required to in the cytokine cocktail to induce differentiation of MUTZ-3 to 
monocytes.
IL-3, MCSF & SCF are potent haematopoietic growth factors which have been 
suggested to activate monocytes in immunoregulatory roles. Also IL3 activity is 
known to require co-stimulation with other cytokines, while FLT3L cannot stimulate 
differentiation without synergising with other CSFs and interleukins to induce growth 
and differentiation. TPO is known to be a lineage specific growth factor which or may 
not induce monocyte formation in MUTZ-3. Thus, to reduce the amount of cytokines 
required for the differentiation of MUTZ-3 to monocytes, the cytokine content of each 
sample was varied by removing only one cytokine from the cocktail o f five cytokines 
(see figure 4).
So far all the experiments were conducted with the cells and cytokines being in 
complete aMEM+. However, to test the significance of the 5637 conditioned medium 
on the growth and differentiation of MUTZ-3, two experiments were conducted in 
parallel: one using complete aMEM' and one using complete aMEM+.
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6.2 Results and Discussion
6.2.1 Spill-over compensation
To prevent spill-over contamination during the flow cytometry the wells were set up 
as described in chapter 1 with an unstained well followed by a CD45 APC positive 
stain and a CD 13 PE stain for each of the two (red/yellow) channels. CD 13 and CD45 
are both antigens that are expressed on monocytes, granulocytes and their 
haematopoietic precursors, thus make ideal positive controls for these investigations 
(figure 13).
CD45 APC
g>. v
g i f ;
'l 0° 10' 10J 103 
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CD13 PE
Figure 13. Positive controls. The CD45APC and CD13PE conjugated antibodies 
were used as positive controls to allow fo r  compensation during flow  cytometry, as 
>97% o f the MUTZ population is CD45+ and CD13+.
45
M. I Haq MRes Biomedicine Summer 2005
Also, there were two single stains for the known negative isotypes: CD3APC and 
CD19PE. These were used along with an unstained to adjust the FACS machine 
channel voltages to shift the population into the lower left quadrant (i.e. negative 
expression).
Figure 14 shows that the FACS machine was set up to ensure -100% of the negative 
isotype were in the lower left. The 1% in other quadrants represents auto- 
fluorescence.
CD3 APC Isotype
CD3APC Isotype Single Sum
!•/. 1%
fa fe w -A
CD19PE Isotype Single Stain
0% 0%
10° 10’ 10J 10s 
Yellow-,
10*
" * 1 3 3 3 9
Figure 14. Negative Isotype controls. The CD3APC and CD19PE conjugated 
antibodies were used as negative isotype controls.
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Figure 15. MUTZ-3 antigen expression after stimulation with cytokines and w/o conditioned medium. Each set (i.e. All, -TPO, -IL3 etc) was 
individually setup with an unstained, both positive controls and both negative controls (data not shown).
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Figure 16. MUTZ-3 antigen expression after stimulation with cytokines and conditioned medium . Each set (i.e. All, -TPO, -IL3 etc) was individually 
setup with an unstained, both positive controls and both negative controls (data not shown). This experiment was repeated once more and the 
data is summarised in table 3.
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Expression Data Set for  +conditioned medium
All Cytokines TPO -IL3 SCF -MCSF -FLT3L
n =  1 n = 2 n =  1 n = 2 n = 1 n = 2 n =  1 n = 2 n = 1 n = 2 n = 1 n = 2
CD 14 APC+CD1 aPE+ 2% 1% 4% 1% 0% 0% 3% 1% 3% 0% 3% 1%
CD 14APC+CD1 aPE' 28% 27% 28% 25% 20% 21% 25% 22% 25% 18% 26% 21%
CD 14 APC'CD 1 aPE+ 0% 0% 1% 0% 0% 0% 1% 0% 1% 0% 1% 0%
CD 14 APC'CD 1 aPE' 70% 72% 67% 74% 79% 79% 73% 78% 71% 81% 69% 78%
CD 11 c APC+CD14PE+ 16% 17% 20% 19% 12% 10% 16% 16% 10% 12% 15% 15%
CD 11 cAPC+CD 14PE' 16% 16% 18% 18% 7% 10% 9% 8% 8% 8% 9% 10%
CD 11 c APC'CD 14PE+ 20% 20% 18% 19% 7% 14% 5% 6% 9% 9% 10% 10%
CD 11 c A PC C D 14PE' 48% 47% 45% 45% 73% 65% 70% 70% 73% 71% 66% 65%
Table 3. Summary o f the flow cytometry data representing the phenotype o f MUTZ-3 stimulated in complete aMEM+ (n is the number o f  
repeats).
The experiments were only repeated once, and though the data is mostly consistent, this investigation must be repeated further to be conclusive. 
Therefore, the mean and errors cannot be calculated as that might not correctly represent the expression of the MUTZ-3. Unfortunately, due to 
technical errors, the repeat experiment using -conditioned medium failed (hence no data shown).
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Firstly, the main difference in the two sets of data above is that the incubation was 
conducted with and without conditioned medium. This had a major effect on the 
growth and differentiation of the cells as can be seen by CD14+ expression increasing 
2-fold when conditioned medium was used.
complete aMEM+
(+ conditioned medium)
complete aMEM'
(- conditioned medium)
Initial Cell count lxlO5 cells/ml lx l0 5 cells/ml
(seeding cells)
Cell count after 10 day 5.5x105 cells/ml 2.8x105 cells/ml
incubation
Table 4. MUTZ-3 cell count. Cells were counted before and after incubation with 
cytokines cocktails.
Initially the same numbers of cells were seeded in all the wells, however, after 10 
days incubation it can be seen that the doubling time with conditioned medium is -5  
days as opposed to -7  days w/o conditioned medium (table 4). This suggests that 
conditioned media from the 5637 cell line contains various unspecified growth factors 
that are essential for the efficient growth and differentiation o f MUTZ-3 cells.
Secondly, by comparing the two sets o f data, it can be observed that absence of TPO 
has no significant influence on the monocyte population, as CD14+ remains at -25% . 
IL-3, however, appears to be essential to induce monocyte differentiation as there is a 
5% drop from -25%  to -20%  CD14+ expression when IL-3 is removed. SCF, MCSF 
and FLT3L appear to have a lesser though significant effect on inducing monocytic
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CD14+ expression. C D llc + expression is also greatly reduced by almost 15% in the 
absence of IL-3, SCF, MCSF and FLT3L, while C D la+ is very weak (1%) with or 
without the cytokines no matter which is removed.
The data also shows the majority o f monocyte-like cells produced by the stimulation 
with these 5 cytokines are both CD14+ and CD1 lc+ simultaneously, hence the shift in 
the population to the top right quadrant. Also, without TPO the CD14+C D llc+ 
population appears to be 5% greater (20%) than if TPO is contained in the cytokine 
cocktail (15%). However, this data is inconclusive as ideally these experiments must 
be repeated a third time.
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CHAPTER 7
Stimulating MUTZ-3 with retinoic acid
7. I Introduction
7.1.1 Cell differentiation by Retinoic A cid
7.2 Results and Discussion
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7.0 Stimulating MUTZ-3 with retinoic acid
7.1 Introduction
As cytokines are expensive and inducing DC-like or monocytic expression in MUTZ- 
3 using cytokines is also very time consuming (almost 4 weeks from stockpiling and 
stimulating cells till analysis by flow cytometry), it was crucial to test whether any 
other factors might be able to induce monocyte differentiation.
7.1.1 Cell differentiation by Retinoic A cid
Thus retinoic acid (RA) was tested. RA is most commonly used in experiments to 
study neural cell differentiation and gene activation. RA is a vitamin A derivative 
whose pleiotropic effects are suggested to be mediated through specific nuclear RA 
receptors (RARs). RA and RARs have been shown to play a key role in the 
haematopoietic system by inducing the proliferation and differentiation of 
haematopoietic progenitors. The exact mechanisms by which RA and RAR regulate 
haematopoietic differentiation are largely unknown; however, research suggests that 
RARs play a crucial role in the terminal differentiation of myeloid precursors as over­
expression of RARs has been shown to suppress myeloid cell differentiation (Hu et 
al., 1996; Geissmann et al., 2003). As RA has been shown to induce terminal 
granulocytic differentiation of the HL-60 myeloid leukaemia cell line, it was assumed 
that it would stimulate the differentiation o f other human acute myelogenous 
leukaemia (AML) cell lines. Therefore, as MUTZ-3 is a human leukemia acute 
promyelocytic cell line it might be possible to induce greater monocytic 
differentiation by incubating MUTZ-3 with RA than when MUTZ-3 are stimulated by 
cytokines. Thus, this investigation was conducted with a series of incubations at 12hrs 
and 24hrs with the RA titre being varied to establish the optimum time and 
concentration o f RA required to induce monocytic expression.
53
M. I Haq MRes Biomedicine Summer 2005
7.2 Results and Discussion
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Figure 17. MUTZ-3 after incubation with retinoic acid and complete aMEM. There was no 
control due to the limited number of cells available for this experiment. Ideally, the control 
should have been MUTZ-3 incubated without RAfor 12hrs and 24hrs in complete aMEM'.
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Figure 18. MUTZ-3 phenotype after incubation with retinoic acid and complete aMEM+.
There was no control due to the limited number o f cells available for this experiment. Ideally, 
the control should have been MUTZ-3 incubated without RAfor 12hrs and 24hrs in complete 
aMEM+. However, the initial phenotypic stain (CHAPTER 3) does represent the MUTZ-3 
phenotypic expression without RA but in complete aMEM+.
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This data is preliminary and requires further study. Crucially it needs to be repeated 
with proper controls, i.e. four 100mm dishes, each seeded with 4xl05 MUTZ-3 cells 
and two incubated with and without conditioned medium for 12hrs and two for 24hrs. 
However, it does show CD14+ expression is up-regulated when MUTZ-3 cell line is 
incubated for 24hrs in complete aMEM+ with as little as lOnM RA concentration. 
This -10%  increase in CD14+ after RA stimulation yields 35% CD14+ expression, 
which is the same as when the MUTZ-3 were stimulated with 5 cytokines. Therefore, 
it is appears from this data, that stimulation with RA is a more cost-effective and less 
time consuming method o f inducing monocytic-like cell expression than using 
cytokines. Though the cytokines may induce similar CD14+ expression over 12hr or 
24hr stimulations rather than the 10 day stimulations that have been investigated 
(chapters 4 and 6). This can be tested in future experiments.
Comparing the two sets o f data for complete aMEM" against complete aMEM+, it can 
be observed that conditioned media is required for the enhanced growth of MUTZ-3 
and this shown by an increase of the CD14+ by -10%  for any given RA concentration 
at 12hr incubation. Also, incubating with conditioned medium for 24hrs still produces 
a 10-15% increase yield o f CD14+ than when incubating without conditioned 
medium.
The data for complete aMEM" shows that when incubating MUTZ-3, with lpM  
concentration o f RA for 24hrs, the CD14+ yield decreases by -5%  than if  the 
incubation is for only 12hrs. Therefore suggesting that lpM  RA may potentially be 
inducing the differentiation o f the CD14+ monocytes to immature or mature DC-like.
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Hence, future investigations should study whether Class II expression is increased or 
CD86 and other such maturation markers are expressed. Also RA might induce cells 
to differentiate to macrophages, however, when the plates where checked using the 
phase contrast microscope there were no significantly visible clumps of adherent cells 
and this is a classic attribute of macrophages.
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CHAPTER 8
Discussion
8.1 Measuring MUTZ-3 differentiation
8.2 Effects o f  varying cytokine cocktail on MUTZ-3 monocytic expression
8.3 Differentiation o f MUTZ-3 monocytes by GM-CSF and IL-4
8.4 Effect ofLPS on MUTZ-3
8.5 MUTZ-3 differentiation by Retinoic Acid
8.6 Future investigations
8.7 The future o f DC models
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DCs play a vital role in immunoregulation, thus extensive research into DC gene 
expression and function is being conducted to establish methods for drug 
administration and cures to infections. As DCs play such an important role in disease 
control and autoimmunity, it is important to have a large on-demand supply of DCs in 
order to efficiently establish their functions. However, DCs are currently studied after 
being harvested from bone marrow or peripheral blood. Also DCs can vary in their 
expression and function depending on their origin, so it is crucial to establish a model 
for DC generation as this will enable greater control on the variability of DCs.
A recent study to establish a model for DCs, conducted by Masterson et al, 
demonstrated that the human myeloid leukaemia cell line MUTZ-3 has the ability to 
acquire DC-like phenotype when stimulated by cytokines, despite cytokine 
responsiveness being low on most o f the other cell lines they tested. MUTZ-3 is a 
CD34+ cell line and responds to GM-CSF, IL4 which induce monocytic and DC-like 
expression both in vivo and in vitro. This research has shown MUTZ-3 can behave as 
CD34+ DC precursors. Masterson et al. have shown that MUTZ-3 stimulated with a 
cocktail o f cytokines acquired phenotypes consistent with that of Langerhan and 
intestinal DC (see chapter 1).
In our investigations, cultured MUTZ-3 cell line was stimulated over 10 days with a 
cocktail o f cytokines: (25ng/ml of each) TPO, IL3, MSCF, SCF and FLT3L. This 
stimulation was repeated but removing individual cytokines to establish the 
significance of each o f the 5 cytokines, and the MUTZ-3 were stimulated with GM- 
CSF (lOOng/ml) and IL-4 (lOng/ml) for 7 days, which Masterson et al. have shown to 
induce immature DC-like phenotype.
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8 ./ M easuring M UTZ-3 differentiation
MUTZ-3 myeloid cell line expresses weak CD14+ suggesting the cell line can be 
induced to increase CD14+ monocyte population but stimulation with growth factors. 
MUTZ-3 stimulated by cytokines for 10 days were observed to have increased CD14+ 
expression by 20% and the MUTZ-3 phenotype represented that of monocytes. 
However, this increase in CD 14 may have been greater if  a monocyte-specific 
progenitor population o f MUTZ-3 was stimulated rather than the mixed MUTZ-3 
population, which contains progenitors for granulocytes and other myeloid cells. Due 
to the cells being incubated for 10 days or more (as is the case when GM-CSF and IL- 
4) the presence of some dead cells and debris might have caused auto-fluorescence, 
hence why the negative controls (e.g. CD3APC and CD19PE) have shown a 1-3% 
expression. Also, there were some initial complications with the setup of the FACS 
machine, though these were later resolved with some careful tweaking of the voltage 
and gating settings, thereby allowing for correct spill-over compensations to be made 
to ensure the data was viable. This can be seen by the CD45APC and CD13PE 
quadrant plots in figure 1. Also, the two fluorescence markers APC and PE have do 
not overlap in emission wavelengths, thus there could have been no erroneous spill­
over fluorescence between channels.
8.2 Effects o f  varying cytokine cocktail on M UTZ-3 monocytic expression
IL-3, MCSF & SCF are potent haematopoietic growth factors known to regulate 
immunological responses. The biological activities of IL-3 are reported to differ 
between species but IL-3 is known as a key molecule to activate monocytes, though 
this may depend upon co-stimulation with other cytokines. Our data shows that when 
IL-3 was removed from the cytokine cocktail stimulation, the yield of CD14+
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decreased by -20%  and C D llc + by -15% . This suggests that IL-3 is a major factor 
for inducing CD14+CD11+ monocyte expression in MUTZ-3. IL-3 has been 
implicated in the differentiation of early non-lineage-committed haematopoietic 
progenitor cells into granulocytes, macrophages and megakaryocytes. IL-3 is a 
priming factor for haematopoietic cells that enhances their responsive to factors such 
GM-CSF. IL-3 can also increases expression of CSF receptors, thus potentially 
enhancing the effect of other cytokines or growth factors.
MCSF is produced by endothelial cells, monocytes and granulocytes but is a key 
factor in regulating the growth and differentiation of monocytes. MCSF synergises 
with IL-3 to stimulate the proliferation and differentiation of haematopoietic cells into 
macrophages, and GM-CSF to suppress the generation of macrophage populations 
(Sumimoto et al., 2002; Hope et al., 2000). This explains why the removal of MSCF 
from the cytokine cocktail also decreased CD14+ yield by -20%  and CD1 lc by -15%.
SCF stimulates the proliferation o f myeloid, erythroid and lymphoid progenitors in 
bone marrow cultures and has been shown to act synergistically with other colony 
stimulating factors to stimulate the differentiation o f myeloid lineage cells (Hope et 
al., 2000; Hagihara et al., 2001). The removal o f SCF from the cytokine cocktail 
reduces the expression o f CD14+ by -20%  and CD1 lc+ by -10% .
FLT3L regulates proliferation o f early haematopoietic cells and research by Hagihara 
et al. shows that FLT3L alone cannot stimulate proliferation or differentiation without 
synergises with other CSFs and interleukins. Therefore, removing FLT3L from the 
stimulation cocktail reduced CD14+ by -15%  and C D llc  by -10% , suggesting that
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FLT3L has an effect though this is probably enhanced further by the presence of the 
other cytokines(Hagihara et al., 2001).
TPO is a lineage specific growth factor which appears to have minimal effect on 
inducing monocytes. This is observed by only a 1-2% reduction in CD14+ with the 
removal o f TPO from the cytokine cocktail. This 1-2% could be attributed to auto­
fluorescence and therefore is not significant.
Further experiments will be required to test the minimal amount of cytokines required 
to induce CD14+C D llc + monocyte expression. Also, it is important to establish the 
phenotype o f MUTZ-3 if only stimulated with each individual cytokine before testing 
with varying cytokine cocktails -  adding an extra cytokine each time to the cocktail. 
This will clarify the synergistic or antagonistic response of the cytokines.
8.3 Differentiation o f M UTZ-3 monocytes by GM-CSF and IL-4
GM-CSF regulates the majority of CSF activities and can be associated as a complex 
with proteoglycans to be stored in a biologically inactive form. Although its release 
mechanism is unknown, it might be linked to the presence of other cytokines or 
growth factors. As GM-CSF was initially isolated as a macrophage growth factor it is 
implicated as a major factor in the development o f macrophage and immature DC 
progenitor cells. GM-CSF has been shown to trigger irreversible differentiation of 
monocytes (Hope et al., 2000). However, GM-CSF can act synergistically with MCSF 
to suppress the differentiation. Hope et al. also reported IL-4 synergistically acts with 
GM-CSF in controlling cell growth and differentiation. The exact mechanism by
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which these factors regulate the differentiation of cells is still unknown, but they are 
implicated in maturation o f monocyte-derived immature DCs.
Our MUTZ-3 cells showed CD14+ and CD1 lc+ down-regulation by -20%  and -15%  
respectively, suggesting the monocytes have differentiated into immature DCs. 
However, the cells were first incubated with the cytokine cocktail containing MCSF, 
which may have partially suppressed the differentiation of monocytes to immature 
DC. Therefore, repeating this experiment with the removal of MSCF might enhance 
differentiation to immature DCs. Also, the maturation marker CD83+ expression 
remains unchanged after GM-CSF and IL-4 stimulation, suggesting the cells have not 
matured after differentiating to immature DCs. However, Class II+ expression 
increases 20%, which may be due to the down-regulation of the factors involved in 
antigen internalisation thus increasing expression of MHC Class II.
Cell morphology was also altered after the 7 day incubation and clear dendrite 
extensions were observed on many cells suggesting the formation of immature DC, 
though most cells remained in the veiled form.
8.4 Effect ofLPS on MUTZ-3
LPS activates macrophages and innate immunity as well as inducing maturation of 
immature DC to mature DC. Therefore, to test whether MUTZ-3 would differentiate 
to mature-DC, a 24hr incubation o f MUTZ-3 with LPS was conducted (data not 
shown). However, the cells number in the initial MUTZ-3 population was low, and 
this might account for the lack o f expression of maturation markers CD86+ and 
CD83+. However, this experiment should be repeated using cells that have been 
stimulated by the cytokine cocktail and GM-CSF and IL-4 to optimise the immature
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DC population. The addition of LPS to immature DC population should stimulate 
maturation into mature DC.
Recent studies have shown that the CD 14 forms a receptor for LPS and LBP, 
however, as MUTZ-3 only expresses CD14+ weakly there might not be sufficient 
LPS/LBP receptors present over the 24hrs incubation to induce maturation of MUTZ- 
3. Therefore, to enhance the CD 14+ receptor expression the MUTZ-3 should be 
treated with the cytokine cocktail before incubating with LPS but not GM-CSF or IL- 
4 as these down-regulate CD 14 expression. It would also be better to incubate MUTZ- 
3 for longer than 48hrs with LPS (lOOng/ml) or for less than 48hrs with a lower 
concentration. LPS has been shown to strongly enhance CD14+ in 45hr cultures of 
purified monocytes (Espuelas et al., 2005).
8.5 MUTZ-3 differentiation by Retinoic Acid
Retinoic acid (RA) is a derivative o f vitamin A and has been established as a major 
proliferation and differentiation factor.
Recent studies using retinoic acid to differentiate cells of human leukaemic 
promyelocytes HL-60 showed that significant terminal cell differentiation occurred 
only after a minimum exposure to retinoic acid. Indeed research by Onodera shows 
that granulocytes will differentiate even with RA concentration as low as InM. 
Therefore, a similar effect might be observed when myelomonocytic progenitor cells 
are stimulated with RA (InM ), hence why I tested the effect of RA at varying 
concentrations at 12hrs and 24hrs.
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Indeed, RA stimulated monocytic expression of CD14+ over 24hrs which is a far 
shorter time and cheaper process than incubating MUTZ-3 with cytokine cocktails. 
However, this stimulation will need repeating to establish the optimum concentration 
and length o f incubation required to induce monocytic expression without inducing 
further differentiation to macrophage or immature-DC.
I would recommend incubating MUTZ-3 for 24hrs in complete aMEM+ with RA 
titres o f concentrations 3nM, 5nM and 7nM to establish the minimum amount of RA 
required to induce the CD14+ expression and to reduce any differentiation past this 
stage to immature DC. However, to test this, the MUTZ-3 would need to be cultured 
for longer to increase stocks and ensure a minimum of lx l0 6 cells/ml (i.e. 10 stains). 
Then analyse double-stained cells by flow cytometry for the expression of the 
following antigens: CD3, CD14, CD1 lc, CDla, CD83, CD86, Class I and Class II.
8.6 Future investigations
Crucially it is important to repeat all the experiments conducted throughout this 
project to confirm the findings and optimise the conditions to increase monocytic 
expression o f MUTZ-3. It would be ideal to be able to reduce the incubation period 
for the MUTZ-3 and also reduce the amount o f cytokines required so that only one or 
two of the cytokines are needed (e.g. IL3 and SCF). Also, it would be interesting to 
test the interactions between cytokines and RA to establish which combinations will 
provide the highest yield of MUTZ-3 monocytes.
It is also advisable to sort the initial mixed population o f MUTZ-3 so as to harvest and 
grow the monocyte progenitors only, which could be experimented on to develop the
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DC-like model. This may increase the yield of monocytes and DC-like populations 
after stimulation by cytokines and/or RA.
In the long term, further studies into the molecular signalling pathways that enable 
cytokines and RA to induce MUTZ-3 would allow us to better understand other 
molecules that might optimise the MUTZ-3 monocyte yield.
Additionally, MUTZ-3 could be incubated at varying lengths with cytokines and other 
growth factors to test their effect on differentiating this myeloid cell line. Research on 
other cell lines suggests the use o f viral vectors to regulate translation or expression of 
various intracellular-produced receptors or signalling molecules. Regulation of these 
molecules might increase the harvest of monocytes which could be used in DC 
studies.
8.7 The fu tu re  o f  DC-like models
Dendritic cells are rare leukocytes that are uniquely potent in their ability to present 
antigens and stimulate naive T cells as well as initiating primary immune responses. 
This property has prompted their recent application to therapeutic cancer vaccines as 
well as potential uses in HIV and TB cure development (Durrant and Ramage, 2005). 
DCs have been developed ex vivo to specifically express tumour antigen and then 
administered as cellular vaccines to induce protective and therapeutic anti-tumour 
immunity in animal studies and recent human trials.
Currently most DC cells are harvested from peripheral blood, Langerhan cells, thymic 
cells and bone-marrow, but DC from these sources exhibit individual variability
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(Weigel et al., 2002; Ratta et al., 1998; Mitsui et al., 2004). These models are likely to 
apply with local variations to the DCs found in similar tissue; for example, the 
Langerhan model has been used to study DC function and life-cycle, however, the DC 
found in other stratified epithelia, such as in the lung can vary from those of the 
Langerhan, for example having varying rates o f turnover in the lung as well as rapid 
response mechanisms to recruit DCs into the tissue on antigen entry. It is unclear 
though if any one model can apply to DCs found in other sites and whether blood DC 
behave in the same way as intestinal DC or dermal DC.
Human CD34+ haematopoietic progenitor cells have been purified from bone-marrow 
and can be induced to proliferate and differentiate into DC when cultured with GM- 
CSF and interferon-y (TNF-y). These DC have been characterised by there dendritic 
morphology and DC-like surface phenotype, i.e. the expression of MHC class II+, 
C D la \  CD4+, CD80+, CD86+, CD83+ and CD 14' (Moghaddami et al., 2005).
However, new research conducted on cells such as CD34+ MUTZ-3 by Masterson et 
al. is enabling the development o f a cellular model for DC behaviour and biological 
function in the hope o f being able to clearly understand and study the molecular 
pathways that lead to antigen presentation by DCs, and how this may lead to 
therapeutic effects in our fight against all diseases. We have shown MUTZ-3 
precursors to be efficiently stimulated to provide a viable source of CD14+ 
monocytes. Therefore, MUTZ-3 represents a model for study of DC differentiation 
and maturation. Indeed MUTZ-3 could be used as an unlimited supply of CD34+ DC 
precursors to explain DC pathways and mechanisms.
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